Shima Azadpour

ORCID: 0000-0003-0152-3287
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hematopoietic Stem Cell Transplantation
  • Immune Cell Function and Interaction
  • Platelet Disorders and Treatments
  • Blood groups and transfusion
  • Clinical Nutrition and Gastroenterology
  • T-cell and B-cell Immunology
  • Colorectal Cancer Treatments and Studies
  • Cancer Genomics and Diagnostics
  • Immunotherapy and Immune Responses
  • Natural Compounds in Disease Treatment
  • Heparin-Induced Thrombocytopenia and Thrombosis
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Toxin Mechanisms and Immunotoxins
  • Genetic factors in colorectal cancer
  • Transplantation: Methods and Outcomes
  • COVID-19 and healthcare impacts
  • Erythropoietin and Anemia Treatment
  • Advanced Drug Delivery Systems
  • Childhood Cancer Survivors' Quality of Life
  • Blood transfusion and management
  • Hemoglobinopathies and Related Disorders
  • Iron Metabolism and Disorders
  • Metabolism and Genetic Disorders
  • Phytochemical compounds biological activities
  • Electrospun Nanofibers in Biomedical Applications

Tarbiat Modares University
2019-2023

British Columbia Children's Hospital
2022

University of British Columbia
2022

Hamedan University of Medical Sciences
2019

High Institute for Education and Research in Transfusion Medicine
2012-2013

Iranian Legal Medicine Organization
2011

Despite all recent health-related improvements, anemia remains an extensive global public health issue affecting the lives of about one-fourth world population in a geographically heterogeneous pattern. We, therefore, aimed to illustrate prevalence, severity, most common types, and major determinants among adults Khuzestan, Iran, from 2016 2019.

10.1186/s12889-022-12512-6 article EN cc-by BMC Public Health 2022-01-25

Anti-thymocyte globulin (ATG) is an established approach to decrease chronic GVHD (cGVHD), yet the exact mechanism uncertain. To better understand of action ATG in preventing cGVHD, we evaluated day 100 immune reconstitution known cGVHD cellular biomarkers using patients from randomized Canadian Bone Marrow Transplant Group (CBMTG) 0801 trial, which demonstrated a significant impact on cGVHD. In separate companion biology study, prophylaxis markers at 40 CBMTG patients. Analysis focused...

10.1016/j.bbmt.2019.11.015 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2019-11-19

Chronic graft-versus-host disease (cGvHD) is a major cause of morbidity after hematopoietic stem cell transplantation (HSCT). In large patient populations, we have shown CD56bright natural killer (NK) population to strongly associate with lack cGvHD and hypothesize that these cells function suppress cGvHD. We aimed isolate define the characteristics regulatory NK (NKreg) associated suppression Immunophenotypic evaluation pediatric found be perforin-, Granzyme B-, CD335+. Transcriptome...

10.3324/haematol.2022.280653 article EN cc-by-nc Haematologica 2022-10-06

Abstract Colorectal cancer (CRC), regardless of standard procedures treatment and screening, is still considered one the deadliest cancers in Western world, economically developed Asian countries, especially Iran. The current study was undertaken to investigate whether changes level Cripto‐1 (CR‐1) expression KRAS mutations have a cumulative effect on onset progression CRC. Fifty colorectal tissue samples, including 35 carcinomas with matching adjacent mucosa, 15 adenomas, were chosen for...

10.1002/jcb.29526 article EN Journal of Cellular Biochemistry 2019-11-06

The latest treatments have improved outcomes for patients with hematological malignancies, but relapse, treatment resistance and particularly side effects still remain as common limitations of these treatments. Given the disadvantages existing conventional therapeutic methods, developing more effective drugs less toxicity is paramount importance. Medicinal herbs historically proven their worth a pool potential agents leukemia lymphoma, today they represent rich source recognition new drug...

10.58209/ijbc.14.3.57 article EN cc-by-nc Iranian Journal of Blood and Cancer 2022-09-01
Coming Soon ...